Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

Abstract Background To investigate the prognostic relevance of the time to interval debulking surgery (TTS) and the time to postoperative adjuvant chemotherapy (TTC) after the completion of neoadjuvant chemotherapy (NACT). Methods A retrospective real-word study included 658 patients with histologic...

Full description

Bibliographic Details
Main Authors:	Xingyu Liu, Yingjun Zhao, Xiaofei Jiao, Yang Yu, Ruyuan Li, Shaoqing Zeng, Jianhua Chi, Guanchen Ma, Yabing Huo, Ming Li, Zikun Peng, Jiahao Liu, Qi Zhou, Dongling Zou, Li Wang, Qingshui Li, Jing Wang, Shuzhong Yao, Youguo Chen, Ding Ma, Ting Hu, Qinglei Gao
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	Journal of Ovarian Research
Subjects:	Neoadjuvant chemotherapy Time to interval debulking surgery Time to postoperative adjuvant chemotherapy Advanced epithelial ovarian cancer Prognosis
Online Access:	https://doi.org/10.1186/s13048-023-01164-8

Similar Items

A comparison between primary debulking surgery and primary chemotherapy in patients with advanced ovarian cancer: a retrospective study
by: Mohamed Esmat, et al.
Published: (2018-01-01)

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
by: Kobal Borut, et al.
Published: (2018-09-01)

Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer
by: Kazuto Nakamura, et al.
Published: (2020-08-01)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
by: Shi‐Ping Yang, et al.
Published: (2022-07-01)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
by: Minjun He, et al.
Published: (2021-03-01)

Primary cytoreductive surgery followed by chemotherapy compared to neoadjuvant chemotherapy followed by cytoreduction as a treatment for stage III and IV ovarian cancer (literature review)
by: E. V. Sibirskaya, et al.
Published: (2024-05-01)

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer
by: Forde GK, et al.
Published: (2016-08-01)

No obvious advantage of hyperthermic intraperitoneal chemotherapy after interval debulking surgery in the treatment of advanced ovarian cancer: A retrospective study
by: Mengmeng Lyu, et al.
Published: (2022-09-01)

NEOADJUVANT CHEMOTHERAPY FOR EPITHELIAL OVARIAN CANCER. MODERN METHODS AND PATIENTS SELECTION CRITERIA
by: A. E. Solopova, et al.
Published: (2016-09-01)

Prognostic Role of CRS in High Grade Serous Ovarian Tumour Patients Receiving Neoadjuvant Chemotherapy in a Tertiary Care Hospital of Central India
by: Manal Ashraf Ali, et al.
Published: (2022-05-01)

Primary versus interval debulking surgery in the management of ovarian cancer patients, current data summary
by: Victoria Psomiadou, et al.
Published: (2022-04-01)

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study
by: Yong Jae Lee, et al.
Published: (2022-07-01)

Prognostic Significance of Chemotherapy Response Score in Patients Undergoing Interval Debulking Surgery and Attained Complete Cytoreduction for High-Grade Serous Tubal and Ovarian Carcinoma
by: Anjana J. Santhamma, et al.

Effects of Neoadjuvant Chemotherapy in Ovarian Cancer Patients With Different Germline BRCA1/2 Mutational Status: A Retrospective Cohort Study
by: Mengdi Fu, et al.
Published: (2022-01-01)

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study
by: Yan Gao, et al.
Published: (2019-09-01)

CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
by: Cheng Li, et al.
Published: (2024-05-01)

Optimal debulking surgery in ovarian cancer patients: MRI may predict the necessity of rectosigmoid resection
by: Xiaofang Zhao, et al.
Published: (2024-06-01)

Primary debulking surgery for metastatic cervical adenocarcinoma: A case report
by: Sara M. Davenport, et al.
Published: (2015-11-01)

Serum Albumin as a Predictor of Survival after Interval Debulking Surgery for Advanced Ovarian Cancer (AOC): A Retrospective Study
by: Dairui Dai, et al.
Published: (2022-02-01)

Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? – Our experience from a tertiary cancer institute
by: Monisha Gupta, et al.
Published: (2020-01-01)

Real World Application of Chemotherapy Response Score in High Grade Serous Cancer of the Ovary
by: Federico Ferrari, et al.
Published: (2022-06-01)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
by: Lin H, et al.
Published: (2021-07-01)

Optimal Timing of Surgery after Neoadjuvant Chemotherapy of Breast Cancer
by: Borna Farazmand, et al.
Published: (2017-03-01)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
by: Alberto Farolfi, et al.
Published: (2023-08-01)

Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis
by: Siyuan Zeng, et al.
Published: (2022-07-01)

Interval Debulking Surgery for Advanced Ovarian Cancer in Elderly Patients (≥70 y): Does the Age Matter?
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
by: Cuicui Lyu, et al.
Published: (2021-07-01)

Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas
by: Emma Hidalgo Crespo, et al.
Published: (2022-08-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

Is Optimal Cytoreduction Post Neoadjuvant Chemotherapy the Only Prognostic Factor in Advanced Ovarian Cancer?
by: Pravesh Dhiman, et al.
Published: (2022-07-01)

The Feasibility of Cardiophrenic Lymphnode Assessment and Removal in Patients Requiring Diaphragmatic Resection During Interval Debulking Surgery for Ovarian Cancer
by: Ciro Pinelli, et al.
Published: (2021-08-01)

Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study
by: Hyunji Lim, et al.
Published: (2022-06-01)

Prognostic analysis of peritoneal washing cytology during interval debulking surgery in advanced ovarian cancer
by: Kazuki Takasaki, et al.
Published: (2024-08-01)

Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients
by: Yu-Jin Koo, et al.
Published: (2015-06-01)

Current status of tertiary debulking surgery and prognosis after secondary debulking surgery for recurrent Müllerian epithelial cancer in Japan: a retrospective analysis of 164 patients (KCOG-G1402)
by: Tomoko Hirakawa, et al.
Published: (2017-07-01)

Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy
by: Ponganun Tuntinarawat, et al.
Published: (2024-04-01)

How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
by: Ma T, et al.
Published: (2021-02-01)

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
by: Xiaoli He, et al.
Published: (2021-06-01)

The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer
by: Yuchong Yang, et al.
Published: (2023-05-01)

Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
by: Yinkui Wang, et al.
Published: (2020-12-01)